Giammaria Giuliani (#2106)
- $ 2 B
- Pharmaceuticals
- Switzerland
- M
- 48 Years
Rest in Peace Ask Jeeves, every search comes to an end
County commissioners call on lawmakers to up funding for 911 dispatch systems
Spirit Airlines Is Going Out Of Business; Effective IMMEDIATELY
Pokémon Scalpers Selling Limited-Edition Pop-Tarts For Ridiculous Prices
Bennett says Netanyahu gov't 'boycotting' West Bank settlements amid Carrefour subsidy deal
Golf gear on sale now: Up to 65% off adidas, 45% off Puma, 15% off Mizuno, more
Families across the US can't find childcare — this map shows where it's worst
Median sales surge 61% in a Queens neighborhood that’s now the fifth priciest in NYC
Greg Brockman says his stake in OpenAI is worth nearly $30 billion
TeraWulf Announces Participation in Upcoming Investor and Industry Conferences
About Me
Giammaria Giuliani is a healthcare investor who owns a 5% stake in Royalty Pharma, the world's largest acquirer of pharmaceutical royalties. Royalty Pharma went public in 2020 and has collected revenue slices of blockbuster drugs like Humira, Imbruvica, Lyrica and Xtandi. Giammaria and his brother Mario also own stakes in Swiss investment company HBM Healthcare Investments and a number of biotech firms in the U.S. The brothers share ownership of their family's pharmaceutical company, Giuliani, founded by their great-grandfather Germano in Milan, Italy in 1889. They also own real estate investments in Europe and the U.S., including a planned commercial and residential project on a maritime platform in Monaco.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Giammaria Giuliani’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Giammaria Giuliani’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $2.0B
(May 4, 2026)
© Iconic Billionaires